找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy for Gastrointestinal Malignancies; Ramakrishna Vadde,Ganji Purnachandra Nagaraju Book 2020 The Editor(s) (if applicable) and

[復(fù)制鏈接]
樓主: 驅(qū)逐
31#
發(fā)表于 2025-3-27 00:01:48 | 只看該作者
32#
發(fā)表于 2025-3-27 04:23:02 | 只看該作者
Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy,son for the low treatment response rate in cancer patients. Thus, there is always a quest to understand the tumor heterogeneity in any cancer type. In this chapter, the authors attempted to understand the types and drivers for tumor heterogeneity, especially in gastrointestinal cancers, and discusse
33#
發(fā)表于 2025-3-27 05:35:34 | 只看該作者
Immunocomposition of Gastrointestinal Tract of Gut,rwhelming load of antigens in the form of dietary antigens on a daily basis. The GI tract has played dual role in the body, in that it performs uptake of nutrients and digestion while also performing out the complex and principal task of maintaining immune homeostasis, i.e., maintaining the balance
34#
發(fā)表于 2025-3-27 11:43:56 | 只看該作者
35#
發(fā)表于 2025-3-27 16:05:21 | 只看該作者
36#
發(fā)表于 2025-3-27 19:34:49 | 只看該作者
Immune Cell Therapy Against Gastrointestinal Tract Cancers, the healthcare sector across the globe. Recently advancements in high throughput techniques provide us with a unique opportunity to detect biomarkers and treat various diseases, including GI cancer, more comprehensively. However, most of these approaches are ineffective for treating patients with a
37#
發(fā)表于 2025-3-28 01:23:56 | 只看該作者
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies,se of cancer related deaths. GI cancers are treated by surgery, radiotherapy, and chemotherapy. The overall survival rate (5 years of survival) after the surgery is very poor in patients with GI cancers. To increase the survival rate adjuvant therapies like chemotherapy and radiotherapy were perform
38#
發(fā)表于 2025-3-28 05:57:20 | 只看該作者
39#
發(fā)表于 2025-3-28 06:33:32 | 只看該作者
40#
發(fā)表于 2025-3-28 11:12:25 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 23:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
会东县| 略阳县| 东乡| 巩义市| 南开区| 张北县| 巩留县| 墨玉县| 得荣县| 阳山县| 平凉市| 贺州市| 泸西县| 吴江市| 湖州市| 若尔盖县| 闵行区| 灵璧县| 嵩明县| 绥宁县| 大安市| 金塔县| 抚顺市| 北海市| 天台县| 广安市| 浦东新区| 崇左市| 乌什县| 兴和县| 尉氏县| 平果县| 青铜峡市| 天峨县| 荥经县| 岳池县| 福海县| 尼勒克县| 海兴县| 芜湖县| 郧西县|